Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
GKOS Glaukos
- 158.120
- +1.520+0.97%
Close Jan 8 16:00 ET
- 156.010
- -2.110-1.33%
Pre 04:43 ET
8.72BMarket Cap-53.97P/E (TTM)
159.120High155.350Low761.42KVolume156.040Open156.600Pre Close120.09MTurnover1.43%Turnover RatioLossP/E (Static)55.14MShares159.12052wk High13.04P/B8.44BFloat Cap83.90052wk Low--Dividend TTM53.36MShs Float159.120Historical High--Div YieldTTM2.41%Amplitude14.250Historical Low157.721Avg Price1Lot Size
About Glaukos Company
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Company Profile
SymbolGKOS
Company NameGlaukos
Listing DateJun 25, 2015
Issue Price18.00
Founded1998
CEOMr. Thomas W. Burns
MarketNYSE
Employees907
Fiscal Year Ends12-31
AddressOne Glaukos Way
CityAliso Viejo
ProvinceCalifornia
CountryUnited States of America
Zip Code92656
Phone1-949-367-9600
Websitehttp://www.glaukos.com
Company Executives
- Name
- Position
- Salary
- Thomas W. Burns
- Chairman of the Board and Chief Executive Officer
- 8.65M
- Joseph E. Gilliam
- President and Chief Operating Officer
- 4.18M
- Dr. Tomas Navratil
- Chief Development Officer
- 2.57M
- Alex R. Thurman
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- 2.36M
- Dr. Leana S. Wen, M. Sc.,M.D.
- Independent Director
- 259.00K
- Denice M. Torres, J.D.,M.B.A.
- Independent Director
- 259.00K
- Marc A. Stapley
- Independent Director
- 273.39K
- Aimee S. Weisner
- Independent Director
- 259.00K
- Mark J. Foley
- Lead Independent Director
- 319.38K
- David F. Hoffmeister
- Independent Director
- 262.13K
- Dr. Gilbert H. Kliman, M.D.
- Independent Director
- 259.00K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.